Minimally invasive bioactivated endoprosthesis for vessel repair

• US 5,449,382 A
• Filed: 03/02/1994
• Issued: 09/12/1995
• Est. Priority Date: 11/04/1992
• Status: Expired due to Term

• Current Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Original Assignee: Granke Kenneth, Michael Peck Dayton
• Inventors: Dayton, Michael P.
• Primary Examiner(s): Pellegrino, Stephen C.
• Assistant Examiner(s): PEFFLEY, MICHAEL F
• Application Number:
  US08/204,947
• Time in Patent Office: 559 Days
• Field of Search: 606/191, 606/192, 606/194, 606/198, 623/1, 623/11, 623/12
• US Class Current: 623/1.15
• CPC Class Codes: A61B 17/00234 for minimally invasive surgery A61B17/0218, A61B17/0469, A61B17/12013, A61B17/1285, A61B17/29, A61B17/320016 take precedence
• CPC Class Codes: A61F 2/93 circumferentially expandable by using ratcheting locks
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body

Abstract

A minimally invasive bioactivated endoprosthesis device for vessel repair. The device comprises a stent which is formed from metal or polymers into a predetermined shape which includes a plurality of holes patterned with a desired size, shape and number to provide a desired bending modulus. The stent is then coated with a polymer or is formed from a polymer which contains a bioactive substance which achieves an equilibrium with the surrounding body tissues or fluids, with the equilibrium being controlled by charge distribution, concentration and molecular weight of the bioactive substance in relation to the pore size of the polymeric carrier for controlled prolonged release of said bioactive substance. The bioactive substance may be selected from the group of heparin, hirudin, prostacyclenes and analogs thereof, antithrombogenic agents, steroids, ibuprofen, antimicrobials, antibiotics, tissue plasma activators, rifamicin, monoclonal antibodies, snake venom protein by-products, antifibrosis agents, cyclosporine and mixtures of these bioactive substances for simultaneous multiple treatments. The stent itself may take several distinct configurations, all of which have a predetermined biasing force acting on the diameter of the stent. Preferred is a rolled stent which is provided with a coiled shape to which it tends to return when expanded. Locking tabs are provided to engage the some of the plurality of holes at the maximum expanded size to prevent return to the smaller diameter coiled shape. Alternatively the predetermined bias of the stent may be the expanded size so that the stent is coiled against this bias during insertion.

Claims

1. A minimally invasive bioactivated endoprosthesis device for vessel repair in contact with surrounding body tissues, comprising:

a stent formed from a flat sheet having an appreciable width to thickness to present a substantial surface to said tissues and coiled to a size for use with a blood vessel or other body conduit and including a plurality of holes, said holes being sufficiently large to permit rapid endothelialization, said stent further including at least one tab for cooperative engagement with said holes to form an internally unrestricted stent having a diameter adjusted to a selected size for said blood vessel or other body conduit; and

a polymer forming the exterior surface of said stent for operative contact with said tissue, said polymer having a microporous structure with a predetermined pore size and further including a bioactive substance within said pores for elution from said pores, said pore size being selected in response to the concentration and molecular weight of said substance to achieve equilibrium between said polymer and said tissue to provide a controlled and prolonged release of said bioactive substance to said surrounding body tissue in an amount sufficient to substantially prevent hyperplasia or therapeutically treat said tissue, said stent having a sufficient amount of said substantial surface to support a quantity of said polymer capable of prolonged release of said amount.

2. The device of claim 1, wherein said stent comprises a flat, rectangular strip of stent material sized by the size of the blood vessel or other body conduit where the stent will be placed and biased to take a smaller diameter coiled shape, said strip having locking tabs along one edge for engaging some of the plurality of holes at a maximum desired expanded size to prevent return to the smaller diameter coiled shape.

3. The device of claim 2, wherein said coiled stent is formed by using said edge of said strip on which the tabs are formed as a rotational axis to roll the strip into a tight coil so that the tabs are in the center of said coil so that when said coiled strip is radially unrolled, the form stresses will bias the strip to roll back into the preferred shape and said tab engage said holes formed in said strip to prevent collapse to the biased shape.

4. The device of claim 3 in which said stent is expanded to different selected sizes, depending upon the particular vessel in which it is placed.

5. The device of claim 4, wherein said coiled shape is adapted to assume a stent shape with more than one diameter.

6. The device of claim 1, in which said predetermined shape includes a predetermined bias of said stent to an expanded size such that the unbiased position is that of the intended final shape.

7. The device of claim 6 wherein said stent is compressed to a smaller diameter prior to use with said predetermined bias urging return to the predetermined shape.

8. The device of claim 1, wherein said stent comprises a metallic strip having a polymer coating.

9. The device of claim 8 wherein said polymer is selected from the group of silicone, polyurethane, polyvinyl alcohol, polyethylene, biodegradable polylactic acid polymers, polyglycolic acid polymers, polyesters, hydrogels, tetrafluroethylene and polytetrafluroethylene, fluorosilicone and combinations, copolymers and blended mixtures thereof.

10. The device of claim 9 wherein said stent is formed from a polymer.

11. The device of claim 10 wherein said polymer has sufficient structural integrity to be formed into a stent.

12. The device of claim 11 wherein said polymer is polymethylmethacrylate.

13. The device of claim 1, wherein said bioactive substance is selected from the group of heparin, hirudin, prostacyclenes and analogs thereof, antithrombogenic agents, steroids, ibuprofen, antimicrobials, antibiotics, tissue plasma activators, rifamicin, monoclonal antibodies, snake venom protein byproducts, antifibrosis agents, cyclosporine and mixtures of these bioactive substances for simultaneous multiple treatments.